Oncept IL-2

RSS

feline interleukin-2 recombinant canarypox virus (vCP1338 virus)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 20/08/2020

Authorisation details

Product details
Name
Oncept IL-2
Agency product number
EMEA/V/C/002562
Active substance
vCP1338 virus
International non-proprietary name (INN) or common name
feline interleukin-2 recombinant canarypox virus (vCP1338 virus)
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QL03AX
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
03/05/2013
Contact address

55216 Ingelheim am Rhein
Germany

Product information

14/08/2020 Oncept IL-2 - EMEA/V/C/002562 - IG/1279

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  • Immunostimulants

  • Immunostimulants

Therapeutic indication

Immunotherapy to be used in association with surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, to reduce the risk of relapse and increase the time to relapse (local recurrence or metastasis).

Assessment history

How useful was this page?

Add your rating